Newest Antidepressants on the Market

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

India Today on MSN · 15h

US FDA approves new nasal spray for depression treatment: All about it

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with antid

health.wusf.usf.edu · 1d

FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Business Insider · 1d

JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression

Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.

MT Newswires on MSN · 1d

Johnson & Johnson Secures FDA Approval For Nasal Spray as Depression Monotherapy

Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray Spravato as the first-ever stand-alone therapy for major depressive disorder. The product, which targets the glutamate neurotransmitter in the brain,

pharmaphorum2d

J&J shares data on would-be blockbuster antidepressant

The market for antidepressants is, however, getting more competitive after years of stagnation, with a string of new drugs on or approaching the market including AbbVie’s Vraylar (cariprazine ...

Johnson & Johnson Gets FDA OK For Spravato as Monotherapy

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

GlobalData on MSN14h

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Potential

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Stay Ahead of ...

Science Daily8d

Scientists uncover rapid-acting, low-side-effect antidepressant target

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting ...

Hosted on MSN5d

Russia's antidepressant sales surge amid ongoing conflict

In 2024, the sale of antidepressant drugs in Russia increased by 20%, reaching 16.1 million packages by November, according ...

money.rediff7d

Alembic Gets USFDA Nod for Generic Antidepressant Tablets

Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results